Mazdutide

GLP-1 & incretin drugsApproved in China (2025); not US

Also known as: Xinermei, IBI362

A GLP-1 and glucagon dual agonist approved in China for obesity and type 2 diabetes.

Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.

How it works

Combines appetite reduction (GLP-1) with higher energy use and liver fat burning (glucagon).

Evidence by goal

GoalGradeWhat the grade means
Fat loss & weightBHuman trials (smaller, mixed, or approved outside the US)
Blood sugar & metabolicBHuman trials (smaller, mixed, or approved outside the US)

At a glance

Route
Subcutaneous weekly
Half-life
About 1 week

Reported dosing

Weekly, escalated per the Chinese label.

Timing: Same day each week.

Cycle: Long-term.

From approved labels where they exist, otherwise from published trials and practitioner reports.

Side effects

  • GI effects
  • Raised heart rate

Who should avoid it

  • GLP-1 class warnings

Often combined with

Used alone.

Key findings

Chinese Phase 3 trials supported approval; Phase 3 is ongoing elsewhere.

Where it is legal (Oct 2026)

USNot approved
CanadaNot approved
MexicoNot approved
EUNot approved

Approved in China (2025) only.

Sources

Open Mazdutide in the Peptide Guide Compare all peptides by goal

Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.

Natoorales and e4life.io (Mexico residency and immigration help) are sister businesses founded by Ian Kain.

Scroll to Top